News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Lavelle Erin
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/09/2023 |
4
| Lavelle Erin (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
| 11/02/2022 |
4
| Lavelle Erin (COO & CFO) has filed a Form 4 on Eliem Therapeutics, Inc.|
Txns:
| Granted 170,000 options to buy
@ $3.27, valued at
$555.9k
|
|
| 05/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2022 |
4
| Lavelle Erin (COO & CFO) has filed a Form 4 on Eliem Therapeutics, Inc.|
Txns:
| Granted 170,000 options to buy
@ $8.21, valued at
$1.4M
|
|
| 08/09/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/24/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/25/2019 |
4
| Lavelle Erin (COO) has filed a Form 4 on ALDER BIOPHARMACEUTICALS INC|
Txns:
| Granted 5,842 shares
@ $0
Sold 1,434 shares
@ $13.6676, valued at
$19.6k
|
|
| 02/08/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2018 |
4
| Lavelle Erin (Chief Commercial Officer) has filed a Form 4 on ALDER BIOPHARMACEUTICALS INC|
Txns:
| Granted 300,000 options to buy
@ $14.55, valued at
$4.4M
|
|
| 04/18/2018 |
3
| Lavelle Erin (Chief Commercial Officer) has filed a Form 3 on ALDER BIOPHARMACEUTICALS INC |
|
|